FluoGuide announces approval for listing on Nasdaq First North Growth Market Sweden on the 24 February 2021
February 5, 2021
Copenhagen, Denmark, 5 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) has today received approval for admission to trading on Nasdaq First North Growth Market Sweden (“Nasdaq First North”). The first day of trading on Nasdaq First North is 24 February 2021. Last day of trading on Spotligth will be 15th of February
FluoGuide has applied for and received approval for admission to trading on Nasdaq First North. The first day of trading in the Company’s share on Nasdaq First North is 24 February 2021. Last day of trading on Spotlight Stock Market is 15 February 2021. The reason for the period where the shares can not be traded is due to the necessary registration of all shares in Euroclear system before the first day of trading on Nasdaq First North.
Nasdaq’s decision is conditional upon (i) that nothing occurs in connection with the change of listing venue that could lead to a different assessment by Nasdaq, and (ii) that the Company, no later than two days before the first day of trading, updates its website in accordance with Nasdaq First North Growth Market Rulebook, and (iii) that a sufficient number of qualified shareholders have their shares registered in the Euroclear system and thereby enabling them to be available for trading on Nasdaq First North.
Västra Hamnen Corporate Finance AB has been engaged as Certified Adviser for Fluoguide A/S on Nasdaq First North Sweden
Online presentation and Q&A session
In connection with the change of listing venue, the company will host a online presentation and Q&A session on Thursday, 11 February, at 5 pm CET.
Sign up and access the presentation here: www.ir.live/fluoguide
For further information, please contact:
Morten Albrechtsen, CEO Henrik Moltke, CFO
+45 24 25 62 66 +45 22 44 54 04
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma.